Director, Clinical Data Management

Sherry Wunder is Director, Clinical Data Management at Avenzo Therapeutics. She has more than 25 years of experience in Phase 1 through Phase 4 clinical trials and has experience in oncology clinical development.

She most recently served as Associate Director at Turning Point Therapeutics which was subsequently acquired by Bristol Myers Squibb (BMS) in August 2022. At Turning Point Therapeutics/BMS, she helped to lead the Data Management team to develop and secure NDA approval of AUGTYRO™ (repotrectinib).

Ms. Wunder has also held similar positions in clinical data management at Gilead Sciences, Inc., Janssen Pharmaceutical Companies of Johnson & Johnson, and GlaxoSmithKline.

Ms. Wunder holds an M.S. in Clinical Research and Organization Management from Drexel University and a BSN in Nursing from Alvernia College in Pennsylvania.